A share price of Relay Therapeutics Inc [RLAY] is currently trading at $8.48, up 5.60%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RLAY shares have gain 11.14% over the last week, with a monthly amount glided 31.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on December 12, 2025, when Wells Fargo upgraded its rating to an Overweight but kept the price target unchanged to $13 for it. On April 17, 2025, Wells Fargo initiated with a Equal Weight rating and assigned a price target of $4 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $16 on September 10, 2024. Oppenheimer downgraded its rating to Perform for this stock on September 10, 2024. In a note dated May 10, 2024, Barclays upgraded an Overweight rating on this stock but restated the target price of $15.
Relay Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.77 and $8.70. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $8.48 at the most recent close of the market. An investor can expect a potential return of 53.3% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -39.14%, Pretax Profit Margin comes in at -35.61%, and Net Profit Margin reading is -35.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.43 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.15 points at the first support level, and at 7.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.67, and for the 2nd resistance point, it is at 8.86.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Relay Therapeutics Inc [NASDAQ:RLAY] is 19.14. As well, the Quick Ratio is 19.14, while the Cash Ratio is 2.81. Considering the valuation of this stock, the price to sales ratio is 175.81, the price to book ratio is 2.41.
Transactions by insiders
Recent insider trading involved Patel Sanjiv, President and CEO, that happened on Nov 03 ’25 when 62073.0 shares were sold. See remarks, Rahmer Peter completed a deal on Oct 29 ’25 to sell 21394.0 shares. Meanwhile, See remarks Rahmer Peter sold 19135.0 shares on Oct 28 ’25.
